News

GSK offered $13 per share, which is 81% premium to HGS closing price on 18 April 2012, of $7.17 per share. HGS has partnered Glaxo in the development

As a part of the agreement, MJFF will sponsor the study, owns and shares all the data and results generated by the trial. Further development plans will depend

The study investigated SNG001 in patients representing mild-moderate through to severe asthmatics, who caught a cold, and was well tolerated. The difficult to treat asthma patient catergory were

The trial met its objectives and FDA’s criteria for bioequivalence between RedHill’s once daily RHB-102, and GlaxoSmithKline’s Zofran. RHB-102 is designed to prevent nausea and vomiting over 24

Cisplatin is a chemotherapy drug used to treat various types of cancers, including sarcomas, carcinomas, lymphomas, and germ cell tumors. Cisplatin injection is available in 1mg/mL packages in

Under the collaboration, Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic. Metabolon has developed a proprietary

The FDA approved BINOSTO to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. Utilizing EffRx’s formulation technology, BINOSTO is the first and

Under the agreement, which is subject to satisfaction of certain closing conditions, CTI will make an upfront payment of $15m and issue $15m shares of unregistered preferred stock

SUGARDOWN, a non-systemic dietary supplement, is a complex carbohydrate-based chewable tablet to moderate post-meal blood glucose for those concerned about their blood glucose levels. Boston will manufacture and